



ABN 53 075 582 740

## ASX ANNOUNCEMENT

8 September 2009

---

### \$15 MILLION CAPITAL RAISING

- **Completes \$5.8 million placement to institutional and sophisticated investors, satisfying a condition precedent to Start-up Australia's \$7 million investment in Bionomics**
- **Completes underwriting of \$2.2 million Share Purchase Plan for shareholders**
- **Funds sufficient to support key clinical programs in cancer and anxiety for over 2 years**
- **Dr Peter Jonson to retire as Chairman at the AGM; Chris Fullerton to step up as Chairman**

**Adelaide, Australia:** Bionomics Limited (ASX:BNO) today announced that it has satisfied one of the two outstanding conditions of its Subscription Agreement with Start-up Australia Ventures Pty Ltd ("Start-up") for its \$7 million investment in the Company, and has raised an additional \$8 million.

As previously announced, one of the two conditions of the Start-up investment was Bionomics raising a further \$5 million through private placements to institutional and sophisticated investors. This condition has been satisfied with the raising of \$5.8 million. The only remaining condition will be satisfied when shareholders approve the issue of shares to Start-up at a shareholder meeting to be convened as soon as possible.

The placement price was 24 cents per share, as against the volume weighted average price of Bionomics shares for the 5 day period prior to and including 2 September of 24.03 cents.

The Company has reserved approximately 15% of the capital raising for participation by all eligible shareholders through a Share Purchase Plan ("SPP"), at the same issue price as that offered to institutional and sophisticated investors. The SPP has been fully underwritten by LINWAR Securities Pty Ltd. LINWAR also acted as manager to the placement. The record date for the SPP will be **Monday 14 September 2009** and, on the basis of a T Plus 3 settlement, the last date for purchasing shares to participate in the SPP will be Wednesday 9 September. Further details on the SPP will be provided to shareholders in a separate announcement.

Following completion of the SPP and the placement to Start-up, a total of \$15 million will have been raised. The resulting funds on hand will allow the Company to continue the Phase II clinical trials development of its anti-cancer drug BNC105 and will enable Bionomics to continue with the Phase I clinical development of its drug for the treatment of anxiety,

BNC210. The Company's budgets for the next two years are summarized by the following use of funds table:

<b>Projected Cash Flow to 30 June 2011</b>		<b>A\$M</b>
<b>Capital raise \$15M + Cash 30 June 2009</b>		<b>19.7</b>
<b>Projected income (contracted R&amp;D revenue + net Neurofit contribution)</b>		<b>7.1</b>
<b>Available Funds</b>		<b>26.8</b>
<b>Expenses:</b>		
BNC105 Phase II Clinical Program:		
- Kidney cancer trials:	\$8.1M	
- Mesothelioma (lung cancer) trials:	\$5.5M	
BNC210 Phase Ib Clinical Trials:	\$3.6M	
Working Capital:	\$3.2M	
<b>Total Expenses</b>		<b>(20.4)</b>
<b>Projected cash 30 June 2011</b>		<b>6.4</b>

In the absence of new opportunities or major developments, the Directors have committed not to raise further equity capital for at least two years.

In announcing the capital raising, the Company also announces that Chairman Dr Peter Jonson intends to retire from the board at the end of the Company's Annual General Meeting in November. Mr Chris Fullerton, who joined the board in December 2008, will assume the role of Chairman at that time.

Dr Jonson commented "I am delighted with this significant, new capital raising and by the confidence of Bionomics' shareholders in the potential of BNC105 and BNC210. Both drugs are targeting very serious medical conditions and I am very pleased to have played a role in fostering their development during my five years as Chairman".

Mr Fullerton said "All shareholders owe Peter our gratitude and thanks for his sound leadership of the Board over a period which saw Bionomics transformed into a substantial, well funded company. His strategic input was instrumental in Bionomics identifying and completing two key acquisitions, both of which have had a critical impact on the Company's development".

## FOR FURTHER INFORMATION PLEASE CONTACT:

### **Bionomics Limited**

Dr Deborah Rathjen  
CEO & Managing Director  
+618 8354 6101 / 0418 160 425  
[drathjen@bionomics.com.au](mailto:drathjen@bionomics.com.au)

### **About Bionomics Limited**

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit [www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

*This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of BNC105, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*